BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 22901781)

  • 1. [Is it possible to avoid working on weekends in an Assisted Reproductive Technology program?].
    Belaisch-Allart J; Mayenga JM; Grzegorczyk-Martin V; Grefenstette I; Chouraqui A; Belaid Y; Kulski O
    Gynecol Obstet Fertil; 2012 Sep; 40(9):472-5. PubMed ID: 22901781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes.
    Tremellen KP; Lane M
    Hum Reprod; 2010 May; 25(5):1219-24. PubMed ID: 20215127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome.
    Herrero L; Pareja S; Losada C; Cobo AC; Pellicer A; Garcia-Velasco JA
    Fertil Steril; 2011 Mar; 95(3):1137-40. PubMed ID: 21047635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B; Tremellen K
    Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.
    Griesinger G; Kolibianakis EM; Papanikolaou EG; Diedrich K; Van Steirteghem A; Devroey P; Ejdrup Bredkjaer H; Humaidan P
    Fertil Steril; 2007 Sep; 88(3):616-21. PubMed ID: 17451691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist.
    Var T; Tonguc E; Dogan M; Mollamahmutoglu L
    Gynecol Endocrinol; 2011 Aug; 27(8):558-61. PubMed ID: 20642381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
    Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
    Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles.
    Xu B; Li Z; Zhang H; Jin L; Li Y; Ai J; Zhu G
    Fertil Steril; 2012 Jun; 97(6):1321-7.e1-4. PubMed ID: 22494924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of triggering oocyte maturation with a GnRH agonist in polycystic ovary syndrome: two case reports.
    Honnma H; Hashiba Y; Asada Y; Endo T
    Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):239-40. PubMed ID: 21477915
    [No Abstract]   [Full Text] [Related]  

  • 18. [Endometrial preparation in oocyte recipients].
    Grzegorczyk-Martin V; Mayenga JM; Kulski O; Belaid Y; Grefenstette I; Belaisch-Allart J
    Gynecol Obstet Fertil; 2012 Sep; 40(9):507-10. PubMed ID: 22906698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed embryo transfer in an in-vitro fertilization programme: how to avoid working on Sunday.
    Belaisch-Allart J; Briot P; Allart JP; Dufêtre C; Mussy MA; Adle F; Soria B
    Hum Reprod; 1991 Apr; 6(4):541-3. PubMed ID: 1833418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles.
    Lee JR; Choi YS; Jee BC; Ku SY; Suh CS; Kim KC; Lee WD; Kim SH
    Fertil Steril; 2007 Nov; 88(5):1344-9. PubMed ID: 17548083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.